The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.
Hosted on MSN3mon
Altimmune Stock Up More Than 25% in a Month: Here's Whya novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company has made rapid ...
Current assessments, such as the NAFLD Fibrosis Score, for example, are not sensitive enough to detect early-stage MASH. Novel biomarkers that employ imaging, such as LiverMultiScan, show promise ...
Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the ... of the Chinese Academy of Sciences identified a novel mechanism in understanding the therapeutic mechanism ...
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of ...
OliX is currently developing OLX75016 as a novel therapeutic in treating MASH accompanied by liver fibrosis, and other cardiometabolic indications. Dong Ki Lee, Ph.D., CEO of OliX Pharmaceuticals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results